Physician profile
Jeffrey Scott Anthony
NPI 1245286079
$1,373.10
in general payments reported to CMS, 2019-2025
21 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.70 · 2022: $61.22 · 2023: $408 · 2024: $418 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $351.95 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $169.81 | 2022-2025 | Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $168.58 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $97.67 | 2021-2025 | |
| Novo Nordisk INC | $77.26 | 2021-2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $73.25 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $72.06 | 2023-2024 | Linzess |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.18 | 2025 | Caplyta |
| Lundbeck LLC | $44.38 | 2024-2025 | Rexulti |
| Madrigal Pharmaceuticals | $33.12 | 2025 | Rezdiffra |
| Sanofi-Aventis U.S. LLC | $31.06 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $28.37 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $23.44 | 2025 | Gvoke Hypopen |
| Abbott Laboratories | $22.53 | 2022 | |
| Esperion Therapeutics, INC. | $21.83 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $20.82 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $20.51 | 2023 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $18.91 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Inari Medical, INC. | $17.71 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Aimmune Therapeutics, INC. | $16.59 | 2024 | |
| Exact Sciences Corporation | $14.07 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Anthony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.